GLP
China’s Supreme Court Upholds Semaglutide Patent for Novo Nordisk
China’s Supreme People’s Court upholds Novo Nordisk’s semaglutide compound patent, supporting IP protection.
Over 600,000 Californians Risk Losing Access to GLP-1 Weight-Loss Drugs
California’s Medi-Cal will stop covering GLP-1 weight-loss drugs for weight-loss-only prescriptions, effective Jan. 1, 2026.
Weight-Loss Pill Approval Likely to Prompt Overhaul of Packaged Food and Fast-Food Products
FDA approval of GLP-1 weight-loss pills may prompt food makers and restaurants to shift to high-protein, smaller-portion products.
FDA Approves New Oral Wegovy Pill for 2026, Revolutionizing Semaglutide Administration
Analysis of 2026 semaglutide options: FDA-approved oral Wegovy, injectables, compounded pathways, costs and safety.
How to Taper Off GLP-1 Medications Safely
How to gradually taper GLP-1 meds to curb hunger, prevent rapid weight regain, and stabilize blood sugar with medical guidance, lifestyle changes, and close monitoring.
5 Tools for Tracking GLP-1 Progress
Compare five tools—patient portal, three apps, and printable journals—for logging GLP‑1 injections, weight, injection sites, and side effects to optimize treatment.
How to Prevent Bruising After GLP-1 Injections
Practical tips to reduce bruising after GLP-1 injections: proper site rotation, 90° technique, fresh needles, warm medication, and post-injection pressure.
Tirzepatide Contraindications: Who Should Avoid It?
Who shouldn’t use tirzepatide? Review contraindications, caution conditions, and safer alternatives for diabetes and weight-loss care.
Zepbound Dosing for Weight Loss Beginners
Step-by-step Zepbound dosing for beginners: start at 2.5 mg weekly, titrate to 15 mg, manage side effects, track progress, and pair with diet and strength training.
